US › Healthcare

Intensity Therapeutics, Inc. Common stock (INTS)

US · Healthcare · Biotechnology

$3.35-0.89%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.0M

EPS

$-1.11

EPS estimate

$-0.81

EPS came in at -1.11 against a street estimate of -0.81 — a miss of 37.0%.

Key statistics

Market cap

$11.9M

Forward P/E

0.0

P/B

1.42

Book value

$3.13

EPS (TTM)

$-3.89

52-week high

$43.50

52-week low

$3.21

50-day MA

$4.04

200-day MA

$5.74

Beta

3.08

Analyst view

Analysts rate Intensity Therapeutics, Inc. Common stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $19.33.

Shareholding

Insiders

3.92%

Institutions

35.75%

Largest institutional holders

Fund	Stake
Kingsbury Capital Investment Advisors LLC	15.21%
KMT WEALTH MANAGEMENT, LLC	15.21%
Sentinus, LLC	0.82%
Vanguard Capital Management, LLC	0.81%
NANO CAP NEW MILLENNIUM GROWTH FUND L P	0.77%
Geode Capital Management, LLC	0.70%
Mesirow Fin Investmt Mgmt Intl Equity	0.43%
Vanguard Fiduciary Trust Co	0.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Intensity Therapeutics, Inc. Common stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.